SEC Form 424B3 filed by Jupiter Neurosciences Inc.
$JUNS
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
8-K - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
S-8 - JUPITER NEUROSCIENCES, INC. (0001679628) (Filer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
4 - JUPITER NEUROSCIENCES, INC. (0001679628) (Issuer)
Advancing FDA-Cleared Phase IIa Parkinson's Program Targeting Neuroinflammation Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia™ JUPITER, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that management will participate in the BIO Investment and Growth Summit 2026, hosted by the Biotechnology Innovation Organization (BIO), taking place March 2 to 3, 2026 in Miami Beach, Florida. The Company's corporate presentation is scheduled for March 2, 2026, at 2:30 PM. At BIO, Jupiter will discuss its FDA-cleare
JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida. The invitation-only event will convene a select group of accredited and high net worth investors for focused discussions on emerging investment opportunities. The event is being organized by the Money Channel NYC. Jup
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company's Standby Equity Purchase Agreement. Under the amendment: Monthly installment payments will now begin on April 1, 2026Principal repayments will follow a defined schedule agreed